Novel sulfur-containing silibinin derivative as well as preparation method and application thereof

By introducing groups such as thiol and tertiary amines on silybin, a new sulfur-containing silybin derivative was designed, which solved the problem of poor solubility of silybin and significantly improved its bioavailability and antioxidant activity. , used to effectively treat liver diseases.

CN118894848AActive Publication Date: 2024-11-05CENT SOUTH UNIV +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410952499.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-05
Estimated Expiration
2044-07-16

AI Technical Summary

Technical Problem

Silybin has low oral bioavailability due to its poor solubility, which limits its use in clinical applications, especially in the treatment of liver diseases such as non-alcoholic fatty liver disease.

Method used

A new series of new sulfhydryl antioxidant active groups were designed by introducing thiol antioxidant active groups at the C23 position of silybin and synthesizing their sulfide dimers and thioester compounds, while introducing hydrophilic tertiary amines at the C6 and C8 positions. Sulfur-containing silybin derivatives to improve their antioxidant activity and solubility.

Benefits of technology

The new sulfur-containing silybin derivative significantly improves oral bioavailability, has better antioxidant activity and liver protection effect, can effectively improve liver function and reduce liver damage indicators, and is used to prevent and treat various causes. Emergency and chronic liver injury, including non-alcoholic steatohepatitis and liver fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894848A_ABST
    Figure CN118894848A_ABST
Patent Text Reader

Abstract

The invention discloses a novel sulfur-containing silibinin derivative as well as a preparation method and application thereof. The novel sulfur-containing silybin derivative is shown as a formula (I), and C2-C3 is a carbon-carbon single bond or a carbon-carbon double bond; r1 is H, a fatty acyl group, an aromatic acyl group, a sulfonyl group, a carbamoyl group, a thiocarbamoyl group or R4; r2 and R3 are H or alkyl substituted amine methylene. The silybin derivative and the medicinal salt thereof can be used for preparing liver protection medicines. The sulfur-containing silibinin derivative disclosed by the invention has relatively good antioxidant activity and free radical scavenging activity. The representative compound 2 can effectively improve the liver function, reduce the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase, improve the liver oxidative stress level and relieve acute liver injury and chronic liver injury. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a novel sulfur-containing silybin derivative and a preparation method thereof and application thereof in protecting the liver and the like. Background Art

[0002] The liver is the largest digestive gland in the human digestive system. When the liver is continuously stimulated by viruses, alcohol, drugs, etc., it may cause liver cell damage and then develop into liver disease. According to statistics, about 2 million people die from liver disease every year. Among them, non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease in the world. It is estimated that the number of people suffering from NAFLD has reached 25% of the world's total population and will continue to increase in the next 10 years. NAFLD can be divided into early primary fatty liver, fatty hepatitis, liver fibrosis stage, and finally cirrhosis and liver cancer stage according to the degree of liver tissue lesions. Non-alcoholic fatty hepatitis (NASH) is the key transition stage from NAFLD to hepatocellular carcinoma. The liver pathology at this stage can still be reversed. How to control the degree of liver fibrosis and reverse liver damage at this stage is particularly important.

[0003] Silymarin is a class of polyphenolic flavonoid lignin compounds with antioxidant activity extracted and separated from the seeds of the Asteraceae plant, Silybum marianum. Silybin is the main liver-protective active ingredient of Silybum marianum and has been used to treat various liver diseases and protect the liver from oxidative stress, inflammation, fatty degeneration, fibrosis and liver cancer. However, due to the poor solubility of silybin, its oral bioavailability is very low (less than 1%), which greatly limits its clinical application. Summary of the invention

[0004] One of the purposes of the present invention is to provide a new class of sulfur-containing silybin derivatives, the structure of which is shown in formula (I):

[0005]

[0006] Among them, (1) there is a carbon-carbon single bond -CH-CH- or a carbon-carbon double bond -C=C- between C2 and C3.

[0007] (2) R1 is H, fatty acyl, aromatic acyl, sulfonyl, carbamoyl, thiocarbamoyl or R4,

[0008] R4 is shown below:

[0009]

[0010] (3) R2, R3 are H or alkyl substituted amine methylene.

[0011] Preferably, the novel sulfur-containing silybin derivatives include but are not limited to compounds represented by Formulae 1 to 15:

[0012]

[0013] The second object of the present invention is to provide a method for preparing the novel sulfur-containing silybin derivatives. The technical route of the method for preparing the silybin derivatives is as follows:

[0014]

[0015]

[0016] (1) Preparation of Compounds 1 and 4

[0017] Under the protection of nitrogen, triphenylphosphine is dissolved in anhydrous tetrahydrofuran, and diisopropyl azodicarboxylate is slowly added dropwise under the condition of stirring in an ice bath. After the addition is completed, a white precipitate is observed. Then, silybin or 2,3-dehydrosilybin dissolved in anhydrous tetrahydrofuran is added to the reaction solution, and finally thioacetic acid is added, and the reaction is restored to room temperature for 30 minutes. After the reaction is completed, it is extracted with ethyl acetate, the organic phase is combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent is spin-dried and separated and purified by silica gel column chromatography to obtain compounds 1 and 4; the molar mass ratio of silybin or 2,3-dehydrosilybin, triphenylphosphine, diisopropyl azodicarboxylate, and thioacetic acid is 1:1~6:1~6:1~6, and the amount of the solvent tetrahydrofuran is 1~50 ml per 1 gram of silybin.

[0018] (2) Preparation of Compounds 2 and 5

[0019] Compound 1 or compound 4 was dissolved in 1M HCl / MeOH solution and stirred at room temperature for 3-4 hours. After the reaction was completed, the mixture was extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, the solvent was dried by spin drying, and purified by silica gel column chromatography to obtain compounds 2 and 5. The amount of 1M HCl / MeOH solution used was 1-50 ml per 1 gram of compound 1 or 4.

[0020] (3) Preparation of Compounds 3 and 6

[0021] Compound 2 or compound 5 is subjected to a condensation reaction under the action of an oxidant iodine for about 10 to 20 minutes. After the reaction is completed, the mixture is quenched with a saturated sodium thiosulfate solution, extracted with ethyl acetate, the organic phases are combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent is dried to obtain compounds 3 and 6; the molar mass ratio of the compound 2 or 5 to the iodine element is 1:0.1 to 3, the solvent used is dimethyl sulfoxide, and 1 to 50 ml of the solvent is used for every 500 mg of compound 2 or 5.

[0022] (4) Preparation of compounds 7 to 15

[0023] Compound 1 or compound 2 is dissolved in methanol, 37% formaldehyde aqueous solution and corresponding secondary amine are added in sequence, reacted at room temperature for 12 to 30 hours, extracted with dichloromethane after the reaction is completed, the organic phases are combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent is spin-dried and separated and purified by silica gel column chromatography to obtain compounds 7 to 15. The molar mass ratio of the compound 1 or 2, 37% formaldehyde aqueous solution, and the corresponding secondary amine is 1:0.5-4:0.5-4, and the amount of the solvent methanol used is 1-25 ml per 250 mg of compound 1 or 2.

[0024] The third object of the present invention is to provide the novel sulfur-containing silybin derivatives and pharmaceutically acceptable salts thereof for use in preparing liver protection drugs.

[0025] The novel sulfur-containing silybin derivative provided by the present invention has good antioxidant activity and free radical scavenging activity. Representative compound 2 can effectively improve liver function, reduce the levels of alanine aminotransferase and aspartate aminotransferase, improve the level of liver oxidative stress, and relieve acute liver injury and chronic liver injury. At the same time, rat experiments show that the oral bioavailability of compound 2 is 28 times that of silybin, and can be used to prevent and treat acute and chronic liver injury caused by various reasons, including non-alcoholic fatty hepatitis, alcoholic fatty hepatitis, drug-induced liver injury, liver fibrosis, cirrhosis, etc.

[0026] The present invention uses a semi-synthetic method to prepare silybin C 23 The antioxidant active group thiol was cleverly introduced, and then its thioether dimer and a series of silybin C were synthesized. 23 A series of new sulfur-containing silybin derivatives were designed and synthesized by introducing hydrophilic tertiary amines at the C6 and C8 positions to improve solubility. Compared with silybin, these new sulfur-containing silybin derivatives have better antioxidant activity and solubility. This type of new sulfur-containing silybin derivatives has good value in the development and utilization of liver protection drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The proliferation inhibitory activity of silybin and its sulfur-containing derivatives 1-5 on HSC-T6 cells;

[0028] Figure 2 Effects of compound 2 on body weight growth rate (A) and liver index (B) in rats with acute liver injury induced by CCl4;

[0029] Figure 3 Effects of compound 2 on the pathological morphology of liver tissue in rats with acute liver injury (A) and the area of ​​oil droplets stained with Oil Red O (B);

[0030] Figure 4 Effects of compound 2 on serum liver injury indicators AST (A), ALT (B), and LDH (C) in rats with acute liver injury;

[0031] Figure 5 Effects of compound 2 on SOD (A) and MDA (B), the oxidative stress indicators of acute liver injury in rats;

[0032] Figure 6 Effects of compound 2 on body weight growth rate (A) and liver index (B) in mice with chronic liver injury induced by CCl4 and high-fat diet

[0033] Figure 7 Effects of compound 2 on liver morphology (A), liver tissue pathology (B), oil droplet area stained with Oil Red O (C), and fibrosis area stained with Masson (D) in mice with chronic liver injury;

[0034] Figure 8 Effects of compound 2 on liver function indicators ALT (A) and AST (B) of mice with chronic liver injury;

[0035] Fig. 9 Effects of compound 2 on blood lipid levels of TG (A), CHO (B), LDL (C), and HDL (D) in mice with chronic liver injury;

[0036] Fig.10 Effects of compound 2 on SOD (A), MDA (B), and GSH-Px (C), indicators of oxidative stress in chronic liver injury in mice;

[0037] Fig.11 Blood concentration-time curves of silybin and compound 2 in rats. DETAILED DESCRIPTION

[0038] Example 1

[0039] Preparation of compound 1

[0040]

[0041] Under nitrogen protection, triphenylphosphine (3.144 g, 12 mmol, 3 eq) was dissolved in 30 ml of anhydrous tetrahydrofuran, and diisopropyl azodicarboxylate (DIAD, 2.360 ml, 12 mmol, 3 eq) was slowly added dropwise at 0°C. After the addition was completed, a milky white precipitate was observed to form. Silybin (1.928 g, 4 mmol, 1 eq) and thioacetic acid (0.857 ml, 12 mmol, 3 eq) dissolved in 10 ml of anhydrous tetrahydrofuran were added to the reaction solution and then heated to room temperature. The reaction solution was stirred at room temperature for 30 minutes and the reaction progress was monitored by TLC. After the reaction, calcium bromide (4.797 g, 24 mmol, 6 eq) was added to the reaction solution, and the mixture was stirred at room temperature for 4 h. A white precipitate was observed. The triphenylphosphine oxide-calcium bromide complex was removed by filtration. The filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography with an eluent of PE / DCM / EA=4 / 2 / 1 (v / v / v) to obtain compound 1 (1.5316 g, yield 71%) as a light yellow solid. 1 H NMR (500MHz, DMSO-d6) δ11.89(s,1H),10.85(s,1H),9.23(s,1H),7.11(dd,J=4.0,2.0Hz,1H),7.03(d,J=7.6Hz, 2H),6.97(dd,J=8.3,1.8Hz,1H),6.88(dd,J=8.2,1.9Hz,1H),6.83(d,J=8.1Hz,1H),5.92(d,J=2.1Hz,1H),5.88 (t,J=2.4Hz,1H),5.82(d,J=6.2Hz,1H),5.09(d,J=11.3Hz,1H),4.83(d,J=7.8Hz,1H),4.61(dt,J=11.7,6.0Hz, 1H), 4.38 (m, J = 4.3Hz, 1H), 3.79 (s, 3H), 3.08 (dd, J = 14.1, 3.5Hz, 1H), 2.95 (dd, J = 14.1, 7.6Hz, 1H), 2.33 (s, 3H). 13 C NMR (126MHz, DMSO-d6) δ198.2,194.7,170.8,167.3,163.8,162.9,148.2,147.8,143.7,143.4,131.1,127.1,121.9,121.3,117.1,1 16.8,115.9,112.3,101.0,96.5,95.5,82.9,78.4,76.1,71.9,60.2,56.2,30.9,30.1,21.2,14.6.HRMS(ESI)m / z[M+H]+calcd.For[C 27 H25 O 10 S]+,541.1163; found 541.1165.

[0042] Example 2

[0043] Preparation of compound 2

[0044]

[0045] Compound 1 (2.16 g, 4 mmol, 1 eq) was dissolved in 1 mol / L hydrochloric acid methanol solution (20 mL, 5 eq), and the reaction solution was reacted at 40 ° C for 4 h. The reaction progress was monitored by TLC. After the reaction was completed, water was added to quench, and ethyl acetate (3×50 mL) was used for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography with an eluent of PE / EA=2 / 1 (v / v) to obtain a light yellow solid compound 2 (1.43 g, yield 72%). 1 H NMR(500MHz,DMSO-d6)δ11.90(s,1H),10.88(s,1H),9.24(s,1H),7.11(dd,J=3.9,1.9Hz,1H),7.06 –7.02(m,2H),7.01(dd,J=8.3,1.7Hz,1H),6.89(d,J=8.0Hz,1H),6.82(d,J=8.1Hz,1H),5.92(d,J= 2.1Hz,1H),5.88(t,J=2.6Hz,1H),5.84(d,J=6.2Hz,1H),5.09(d,J=11.3Hz,1H),4.91(d,J=7.6Hz, 1H),4.62(dt,J=11.4,6.6Hz,1H),4.36–4.30(m,1H),3.79(s,3H),2.65(m,1H),2.56–2.47(m,1H). 13 C NMR (151MHz, DMSO-d6) δ198.3,167.3,163.8,162.9,148.3,147.7,143.7,130.9,127.4,122.0,121.8,121.1,117.2,117.1,11 6.9,116.8,115.9,112.1,100.9,96.5,95.5,82.9,77.9,77.4,71.9,60.2,56.2,25.4,14.6.HRMS(ESI)m / z[M+H]+calcd.For[C 25 H 23 O9S]+,499.1057; found 499.1052.

[0046] Example 3

[0047] Preparation of compound 3

[0048]

[0049] Compound 2 (50 mg, 0.1 mmol, 1 eq) was dissolved in 1 ml DMSO, iodine (12.5 mg, 0.05 mmol, 0.5 eq) was added, and the mixture was stirred at room temperature for 30 min. The reaction progress was monitored by TLC. After the reaction was completed, a saturated sodium thiosulfate solution was added to quench the reaction, and EA (3×10 mL) was used for extraction. The organic phases were combined, washed three times with a saturated NaCl solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the target compound 3 (47.8 mg, yield 96%) as a white solid. 1 H NMR (500MHz, DMSO-d6) δ11.89(s,1H),10.86(s,1H),9.22(s,1H),7.11(d,J=6.0Hz,1H),7.02(dd,J=14 .0,6.4Hz,2H),6.92–6.86(m,1H),6.82(d,J=11.0Hz,2H),5.93(d,J=2.0Hz,1H),5.88(dt,J=3.2,1.9H z,1H),5.84(dd,J=6.3,2.7Hz,1H),5.10(d,J=11.5Hz,1H),4.86–4.82(m,1H),4.63(dd,J=14.5,10.4H z,1H),4.45(dt,J=7.7,3.4Hz,1H),3.76(s,3H),2.93(dd,J=17.7,6.4Hz,1H),2.80(d,J=13.8Hz,1H). 13 C NMR (126MHz, DMSO-d6) δ198.2,167.3,163.8,162.9,148.3,147.7,143.6,143.3,131.0,127.2,122.0,121.8,121.2,121. 1,117.2,117.1,116.8,115.9,112.1,100.9,96.5,95.5,82.9,78.0,76.0,71.9,56.1.HRMS(ESI)m / z[M+H]+calcd.For[C 50 H 43 O 18 S2]+,995.1885; found 995.1885.

[0050] Example 4

[0051] Preparation of compound 4

[0052]

[0053] Referring to the synthesis method of compound 1, 312 mg of yellow solid compound 4 was obtained from the raw material dehydrogenated silybin (0.960 g, 2 mmol), with a yield of 28%. 1 H NMR(500MHz,DMSO-d6)δ12.41(s,1H),10.84(s,1H),9.63(s,1H),9.26(s,1H),7.77(d,J=9.3H z,2H),7.11(d,J=8.4Hz,1H),7.06(d,J=1.9Hz,1H),6.90(dd,J=8.1,1.9Hz,1H),6.84(d,J=8.1 Hz,1H),6.46(d,J=2.1Hz,1H),6.20(d,J=2.1Hz,1H),4.89(d,J=7.7Hz,1H),4.48(td,J=7.7,3. 4Hz,1H),3.80(s,3H),3.09(dd,J=14.1,3.5Hz,1H),2.97(dd,J=14.2,7.7Hz,1H),2.34(s,3H). 13 C NMR (126MHz, DMSO-d6) δ194.7,176.5,164.6,161.2,156.7,148.3,147.9,146.0,144.7,143.8,136.9,126.9,124.7,121.9,121.4,117.3 found 539.1010.

[0054] Example 5

[0055] Preparation of compound 5

[0056]

[0057] Referring to the synthesis method of compound 2, 280 mg of yellow solid compound 5 was obtained from raw material compound 4 (0.992 g, 2 mmol), with a yield of 28%. 1H NMR(500MHz,DMSO-d6)δ12.41(s,1H),10.84(s,1H),9.62(s,1H),9.24(s,1H),7.78(d, J=9.4Hz,2H),7.16(d,J=8.5Hz,1H),7.07(d,J=2.0Hz,1H),6.92(dd,J=8.1,2.0Hz,1H) ,6.83(d,J=8.1Hz,1H),6.47(d,J=2.0Hz,1H),6.20(d,J=2.0Hz,1H),4.96(d,J=7.6Hz, 1H), 4.44 (dt, J=9.2, 5.9Hz, 1H), 3.80 (s, 3H), 2.71–2.64 (m, 1H), 2.57 (q, J=7.4Hz, 1H). 13 C NMR (126MHz, DMSO-d6) δ176.5,164.6,161.2,156.7,148.3,147.8,146.1,145.0,143.8,136.9,127.2,124.6,121.8,121.1,117.4,116.7, found 497.0903.

[0058] Example 6

[0059] Preparation of compound 6

[0060]

[0061] Referring to the synthesis method of compound 3, 44 mg of yellow solid compound 6 was obtained from raw material compound 4 (50 mg, 0.1 mmol), with a yield of 88%. 1H NMR(500MHz,DMSO-d6)δ12.29(s,1H),10.72(s,1H),9.40(s,1H),9.27(s,1H),7.75–7 .72(m,1H),7.58(d,J=2.1Hz,1H),7.04(d,J=8.1Hz,2H),6.88(d,J=7.5Hz,1H),6.84(d ,J=8.1Hz,1H),6.33(d,J=2.0Hz,1H),6.13(d,J=2.0Hz,1H),4.86(d,J=7.6Hz,1H),4. 53(t,J=6.1Hz,1H),3.81(s,3H),2.92(dd,J=14.5,8.6Hz,1H),2.72(d,J=13.3Hz,1H). 13 C NMR (126MHz, DMSO-d6) δ176.2,164.4,161.1,156.5,148.3,147.8,145.7,144.2,143.5,136.8,127.0,124.8,121.8,121.2,117.1,116.5,1 16.0,112.1,103.4,98.6,93.9,77.9,75.7,56.2,22.6,14.4.HRMS(ESI)m / z[M+H]+calcd.For[C50H39O18S2]+,991.1572; found991.1570.

[0062] Example 7

[0063] Preparation of compound 7

[0064]

[0065] Compound 1 (108 mg, 0.2 mmol, 1 eq) was dissolved in 6 mL of methanol. 37% formaldehyde aqueous solution (7.5 μL, 0.1 mmol, 0.5 eq) and 40% dimethylamine aqueous solution (12.7 μL, 0.1 mmol, 0.5 eq) were added to the reaction solution in sequence. The mixture was stirred at room temperature for 18 h. The reaction progress was monitored by TLC. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product. The crude product was purified by flash silica gel column chromatography with an eluent of DCM / MeOH=30 / 1-10 / 1 (v / v) to obtain 47 mg of compound 7 as a white solid with a yield of 39%. 1HNMR(500MHz, CDCl3)δ7.15(dd,J=5.2,2.1Hz,1H),7.08–7.05(m,1H),7.02(dd,J=8.2,2.1Hz,1H) ,6.96(d,J=8.7Hz,1H),6.92–6.88(m,2H),6.04(d,J=5.6Hz,1H),4.95(d,J=11.3Hz,1H),4.74(d,J =7.5Hz,1H),4.49(dd,J=11.9,6.1Hz,1H),4.26–4.20(m,1H),4.12(q,J=7.1Hz,1H),3.93(s,3H), 3.91(s,2H),3.23(dd,J=14.0,3.7Hz,1H),2.86(dd,J=14.0,7.2Hz,1H),2.56(s,6H),2.33(s,3H). 13 C NMR (126MHz, CDCl3) δ195.0,194.8,171.9,162.7,160.8,147.2,146.8,143.8,129.9,127.7,121.3,121.2,117. 5,117.4,116.6,114.8,109.7,100.8,99.0,97.2,82.9,78.7,76.1,72.3,56.19,56.18,54.5,44.0,30.62,29.8.

[0066] Example 8

[0067] Preparation of compound 8

[0068]

[0069] Referring to the synthesis method of compound 7, 44 mg of white solid compound 8 was obtained from the raw material compound 2 (100 mg, 0.2 mmol), with a yield of 40%. 1H NMR(500MHz,DMSO-d6)δ7.08(t,J=2.3Hz,1H),7.04(t,J=1.5Hz,1H),7.01–6.99(m,2H),6 .89(dd,J=7.9,1.9Hz,1H),6.82(d,J=8.1Hz,1H),5.54(d,J=2.6Hz,1H),4.96(dd,J=10.8, 1.5Hz,1H),4.90(d,J=7.6Hz,1H),4.46(dd,J=10.9,8.2Hz,1H),4.32(qd,J=6.4,3.3Hz,1H ),3.83(s,2H),3.79(s,3H),2.65(dd,J=14.5,3.5Hz,1H),2.57–2.52(m,1H),2.51(s,6H). 13 C NMR(126MHz,DMSO-d6)δ194.9,175.2,162.2,161.9,148.3,147.8,143.6,143.5,131.,127.4,121.6, 121.1,117.0,116.8,115.9,112.2,100.2,97.5,97.1,82.6,77.9,77.4,71.7,56.2,53.2,43.0,25.5.

[0070] Example 9

[0071] Preparation of compound 9

[0072]

[0073] Compound 1 (108 mg, 0.2 mmol, 1 eq) was dissolved in 6 mL of methanol. 37% formaldehyde aqueous solution (7.5 μL, 0.1 mmol, 0.5 eq) and diethylamine (10.3 μL, 0.1 mmol, 0.5 eq) were added to the reaction solution in sequence. The mixture was stirred at room temperature for 24 h. The reaction progress was monitored by TLC. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product. The crude product was purified by flash silica gel column chromatography with an eluent of DCM / MeOH=30 / 1-10 / 1 (v / v) to obtain 50 mg of compound 9 as a white solid with a yield of 40%. 1H NMR(500MHz,DMSO-d6)δ7.07(t,J=2.6Hz,1H),7.05–6.97(m,3H),6.94(dd,J=8.5,1.6Hz,1H),6.87(dd ,J=8.1,2.0Hz,1H),6.82(d,J=8.0Hz,1H),5.53(d,J=2.5Hz,1H),4.96(d,J=10.9Hz,1H),4.82(d,J=7.7 Hz,1H),4.46(dd,J=10.9,7.6Hz,1H),4.37(tdd,J=7.9,5.5,3.6Hz,2H),3.89(s,2H),3.78(s,3H),3.0 7(dd,J=14.0,3.6Hz,1H),2.97–2.89(m,1H),2.83(q,J=7.2Hz,4H),2.32(s,3H),1.13(t,J=7.2Hz,6H). 13 C NMR (126MHz, DMSO-d6) δ194.7,194.3,174.8,161.6,161.1,147.8,147.3,143.2,142.8,131.1,126.7,120.8,1 16.6,116.5,116.3,115.4,111.8,99.2,97.2,96.6,82.1,77.9,75.6,71.2,55.7,47.8,45.8,30.4,29.6,9.7.

[0074] Example 10

[0075] Preparation of compound 10

[0076]

[0077] Referring to the synthesis method of compound 9, 51 mg of white solid compound 10 was obtained from the raw material compound 2 (100 mg, 0.2 mmol), with a yield of 44%. 1H NMR(500MHz,DMSO-d6)δ7.08(t,J=2.3Hz,1H),7.10–6.96(m,3H),6.89(d,J=8.2Hz,1H),6. 82(d,J=8.0Hz,1H),5.53(d,J=2.9Hz,1H),4.96(d,J=10.8Hz,1H),4.90(d,J=7.6Hz,1H),4 .46(dd,J=10.9,8.1Hz,1H),4.32(tp,J=8.7,5.4,4.3Hz,1H),3.89(s,2H),3.79(s,3H),2. 84(q,J=7.3Hz,4H),2.65(dd,J=14.4,3.5Hz,1H),2.57–2.52(m,1H),1.14(t,J=7.2Hz,6H). 13 C NMR (126MHz, DMSO-d6) δ195.2,175.3,162.1,161.6,148.3,147.8,143.7,143.5,131.5,127.4,121.6,121.1,1 17.0,116.8,115.9,112.2,99.8,97.8,97.1,82.6,77.9,77.4,71.7,56.2,48.3,46.3,42.3,25.5,12.6,10.2.

[0078] Embodiment 11

[0079] Preparation of compound 11

[0080]

[0081] Referring to the synthesis method of compound 9, 54 mg of white solid compound 11 was obtained from raw material compound 1 (108 mg, 0.2 mmol) and pyrrolidine (8.2 μL, 0.1 mmol), with a yield of 43%. 1H NMR(500MHz,DMSO-d6)δ7.07(t,J=2.6Hz,1H),7.03–6.99(m,2H),6.94(dd,J=8.3,1.7Hz,1H), 6.87(dd,J=8.1,1.9Hz,1H),6.82(d,J=8.1Hz,1H),5.48(t,J=2.4Hz,1H),4.96–4.90(m,1H),4 .82(d,J=7.7Hz,1H),4.42(m,1H),4.37(m,1H),3.94(s,2H),3.79(s,3H),3.07(dd,J=14.1,3. 6Hz,1H),2.98(d,J=6.6Hz,4H),2.93(dd,J=14.1,7.7Hz,1H),2.32(s,3H),1.90–1.83(m,4H). 13 C NMR (126MHz, DMSO-d6) δ194.3,193.7,175.6,161.6,161.5,147.8,147.4,143.1,142.7,131.3,126.7,121.4,12 0.8,116.6,116.3,115.4,111.8,100.1,96.9,96.5,82.0,77.9,75.6,71.1,55.7,52.6,49.1,30.4,29.6,22.9.

[0082] Example 12

[0083] Preparation of compound 12

[0084]

[0085] Referring to the synthesis method of compound 9, 47 mg of white solid compound 12 was obtained from raw material compound 2 (100 mg, 0.2 mmol) and pyrrolidine (8.2 μL, 0.1 mmol) with a yield of 40%. 1H NMR(500MHz,DMSO-d6)δ7.07(t,J=2.4Hz,1H),7.04–6.97(m,3H),6.89(d,J=8.1H z,1H),6.82(d,J=8.1Hz,1H),5.48(d,J=2.6Hz,1H),4.95–4.88(m,2H),4.42(dd,J =10.8,8.4Hz,1H),4.31(qd,J=6.5,3.3Hz,1H),3.94(s,2H),3.78(s,3H),2.99(d, J=6.4Hz,4H),2.65(dd,J=14.4,3.5Hz,1H),2.57–2.52(m,1H),1.89–1.84(m,4H). 13 C NMR (126MHz, DMSO-d6) δ194.2,176.2,162.1,162.0,148.3,147.8,143.6,143.5,131.6,127.4,121.8,121.1 ,117.0,116.8,115.9,112.2,100.7,97.5,96.9,82.5,77.9,77.4,71.6,56.2,55.4,53.1,49.6,25.5,23.4.

[0086] Example 13

[0087] Preparation of compound 13

[0088]

[0089] Referring to the synthesis method of compound 9, 53 mg of white solid compound 13 was obtained from raw material compound 1 (108 mg, 0.2 mmol) and piperidine (9.9 μL, 0.1 mmol), with a yield of 42%. 1H NMR(500MHz,DMSO-d6)δ7.07(t,J=2.5Hz,1H),7.04–6.99(m,2H),6.95(dd,J=8.3,1.6Hz,1H),6.87(dd, J=8.1,2.0Hz,1H),6.82(d,J=8.1Hz,1H),4.99(d,J=11.0Hz,1H),4.82(d,J=7.7Hz,1H),4.49(dd,J=11. 0,7.1Hz,1H),4.37(tdd,J=8.0,5.0,3.5Hz,1H),3.79(s,5H),3.07(dd,J=14.1,3.6Hz,1H),2.94(dd,J= 14.1,7.6Hz,1H),2.71(t,J=5.4Hz,4H),2.32(s,3H),1.59(t,J=5.8Hz,4H),1.47(q,J=7.6,6.5Hz,2H). 13 C NMR (126MHz, DMSO-d6) δ196.0,194.7,173.2,162.0,161.5,148.3,147.9,143.7,143.3,131.5,127.1,121.7,121. 3,117.0,116.8,115.9,112.3,100.0,98.5,96.7,82.7,78.4,76.1,71.8,56.2,52.7,52.6,30.8,30.1,24.8,23.1.

[0090] Embodiment 14

[0091] Preparation of compound 14

[0092]

[0093] Referring to the synthesis method of compound 9, 42 mg of white solid compound 14 was obtained from raw material compound 2 (100 mg, 0.2 mmol) and piperidine (9.9 μL, 0.1 mmol) with a yield of 35%. 1H NMR(500MHz,DMSO-d6)δ7.12(dd,J=4.1,1.8Hz,1H),7.06–6.99(m,3H),6.89(dt,J=8.1,1.7Hz,1H), 6.83(d,J=8.0Hz,1H),6.13(d,J=4.3Hz,1H),5.75(s,1H),5.16(d,J=11.4Hz,1H),4.91(d,J=7.6Hz,1 H),4.67(dd,J=11.3,7.1Hz,1H),4.33(ddt,J=11.3,8.9,4.4Hz,1H),4.09(s,2H),3.79(d,J=1.4Hz,3 H),3.34(m,2H),2.94(m,2H),2.66(ddd,J=14.0,8.2,3.4Hz,1H),2.55(q,J=7.4Hz,1H),1.69(m,6H). 13 C NMR (126MHz, DMSO-d6) δ198.8,198.7,166.6,163.4,163.3,148.3,147.8,143.8,143.7,130.6,127.4,122.0,12 1.1,117.1,117.0,116.0,112.2,100.6,97.8,95.2,83.2,77.9,77.5,71.8,56.2,55.4,52.8,25.5,22.7,21.5.

[0094] Embodiment 15

[0095] Preparation of compound 15

[0096]

[0097] Compound 1 (108 mg, 0.2 mmol, 1 eq) was dissolved in 8 mL of methanol. 37% aqueous formaldehyde solution (60 μL, 0.8 mmol, 4 eq) and morpholine (71 μL, 0.8 mmol, 4 eq) were added to the reaction solution in sequence. The mixture was stirred at room temperature for 8 h. The reaction progress was monitored by TLC. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product. The crude product was purified by flash silica gel column chromatography with an eluent of DCM / MeOH=30 / 1-10 / 1 (v / v) to obtain 121 mg of compound 15 as a white solid with a yield of 82%. 1H NMR (500MHz, CDCl3) δ7.09–7.05(m,1H),7.01–6.94(m,2H),6.90(d,J=8.2Hz,1H ),6.87–6.82(m,2H),4.85(d,J=11.8Hz,1H),4.69(dd,J=10.0,7.8Hz,1H),4.37 (dd,J=11.8,1.4Hz,1H),4.20(m,1H),3.88(d,J=2.2Hz,3H),3.75–3.57(m,12H) ,3.18(dt,J=14.1,3.2Hz,1H),2.79(m,1H),2.52(d,J=35.6Hz,8H),2.27(s,3H). 13 C NMR (126MHz, CDCl3) δ195.3,194.6,168.4,161.1,159.9,147.2,146.8,143.8,129.7,127.4,121.3,120.8,117.3, 116.4,116.1,114.8,109.7,102.4,101.3,99.2,82.9,78.7,76.0,72.4,66.7,56.1,53.0,52.8,51.4,30.5,30.4.

[0098] Example 16

[0099] In vitro antioxidant activity assay

[0100] 16.1DPPH free radical scavenging experiment

[0101] A 0.2mM DPPH solution and sample solutions of different concentrations (6.25, 12.5, 25, 50, 100, 200mM) were prepared with methanol solution. The assay was performed in a 96-well plate. The test group (A1) consisted of 100μl DPPH solution and 100μl sample solutions of different concentrations in each well, mixed evenly, with three replicate wells for each concentration; the negative control group (A2) consisted of 100μl sample solutions of different concentrations and an equal volume of methanol solution in each well; the blank control group (A0) consisted of 100μl DPPH solution and an equal volume of methanol solution in each well. The mixture was reacted in the dark at room temperature for 30 minutes, and then the absorbance of each well was measured at 517nm by an enzyme reader. Calculation of DPPH free radical scavenging rate: 16.2 Superoxide Anion Radical Scavenging Experiment

[0102] Add 100 μL of 0.05 mol / L Tris-HCl buffer solution (pH 8.2) to a 96-well plate, incubate at 25°C for 20 minutes, add 80 μL of sample solution of different concentrations to each well, incubate at 25°C for 20 minutes, then add 20 μL of 3 mM pyrogallol solution, mix well, react at 25°C for 5 minutes, and then immediately add 20 μL of 10 mM hydrochloric acid solution to terminate the reaction. Then measure the absorbance of each well at 320 nm using an ELISA reader, and take the average value of three replicate wells for each concentration. The blank control is to replace the sample solution with an equal volume of methanol. Calculate the superoxide anion radical scavenging rate:

[0103] 16.3 Iron Reducing Ability Test Experiment

[0104] Mix 250 μL sodium phosphate buffer (0.2 mol / L, pH 6.6) with 250 μL 1% potassium ferricyanide solution in a 1.5 mL centrifuge tube, add 250 μL sample solution of different concentrations, mix well, heat in a 50°C water bath for 20 minutes, and then add 250 μL 10% trichloroacetic acid (w / v). Then centrifuge the centrifuge tube at 1000 rpm for 10 minutes in a centrifuge. After centrifugation, mix 500 μL of the upper layer solution with 500 μL deionized water and 100 μL 0.1% FeCl3, and measure the absorbance at 700 nm. The determination was carried out in a 96-well plate, and the solution volume of 200 μL was added to each well of the 96-well plate. The absorbance of each well was measured at 700 nm using an enzyme reader, and three replicate wells for each concentration were averaged. The blank control was to replace the sample solution with an equal volume of methanol. Calculate the iron reducing ability:

[0105] 16.4 Determination of lipid peroxidation inhibition rate

[0106] (1) Preparation of egg yolk suspension: Remove the egg white from fresh eggs, mix the egg yolk with an equal volume of phosphate buffer (0.1 mol / L, pH 7.4) to make a 1:1 suspension. Stir the mixture magnetically at 37°C for 10 minutes, then dilute it with PBS buffer to a 1:25 egg yolk suspension and refrigerate it for later use.

[0107] (2) Color reaction and determination: 40 μl of the above-mentioned egg yolk suspension, 10 μl of sample solution of different concentrations and 40 μl of FeSO4 solution (25 mMol / L) were added to a centrifuge tube in sequence, and the solution volume was supplemented with PBS buffer to 400 μl, and then the centrifuge tube was incubated at 37°C for 15 minutes. After taking out, 100 μl of 20% trichloroacetic acid solution and 0.8% thiobarbituric acid solution were added to the centrifuge tube, and the mixture was heated in a water bath at 100°C for 15 minutes. After cooling to room temperature, the centrifuge tube was centrifuged at 1000 r / min for 10 minutes, and the supernatant was taken and its absorbance was measured at 532 nm. The determination was carried out in a 96-well plate, and the supernatant was added to the 96-well plate according to a solution volume of 200 μl per well. The absorbance of each well was measured at 532 nm using an ELISA reader, and three replicate wells for each concentration were used to take the average value. The blank control was to replace the sample solution with an equal volume of methanol. Calculation of lipid peroxidation inhibition rate:

[0108] 16.5 Experimental Results

[0109] The in vitro antioxidant activities of compounds 1 to 6 are shown in Table 1. Compared with silybin, most of the new silybin sulfur-containing derivatives showed good in vitro antioxidant activities, especially compounds 2 and 5, which showed higher activities than all tested compounds in DPPH and superoxide anion free radical scavenging experiments. Oxidative stress plays an important role in the development of various liver diseases, so the strong antioxidant activity of these sulfur-containing derivatives will make them excellent in liver protection.

[0110] Table 1 Antioxidant activity of silybin and compounds 1-6

[0111]

[0112] Example 17 Cytotoxicity Experiment

[0113] (1) Plating: Take HSC-T6 cells and perform the same cell passaging procedure. After centrifugation, aspirate the supernatant, add 2 ml of fresh culture medium, pipette evenly, use a pipette to take 20 μl of the cell suspension and add it to a 1.5 ml centrifuge tube containing 180 μl of PBS buffer, mix well, and count the cells using a counting plate. Then dilute to a cell concentration of 5 × 104 cells / ml and add 100 μl per well to a 96-well plate, i.e., 5 × 103 cells per well, and incubate in a cell culture incubator for 12 hours.

[0114] (2) Dosing: Prepare 200 mmol / L compound stock solution with cell-grade DMSO, and dilute it with culture medium to 20, 40, 80, and 120 μmol / L sample solutions. After observing the cells adherent under a microscope, use a spray gun to aspirate the old culture medium in the 96-well plate, add 100 μl of different sample solutions, and set three replicate wells for each sample. Set the blank group to 3 wells with only 100 μl of culture medium, and the control group to 3 wells without sample solution. Then place the 96-well plate in a cell culture incubator and incubate for 24 hours.

[0115] (3) Determination: After the 96-well plate is placed in a cell culture incubator for 24 hours, 20 μl of 5 mg / ml MTT solution is added to each well in a light-proof condition and the plate is incubated for another 4 hours. The 96-well plate is then removed, the old culture medium is aspirated, 100 μl of dimethyl sulfoxide solution is added to each well, and the plate is shaken until the formazan is completely dissolved. The absorbance of each well is measured at 570 nm using a microplate reader.

[0116] (4) Experimental results: Figure 1 (A) Silybin and its sulfur-containing derivative compounds 1 to 3 have no inhibitory effect on the proliferation of HSC-T6 cells at concentrations of 20, 40, and 80 μM. At a concentration of 120 μM, the survival rate of HSC-T6 cells after treatment with compound 1 is basically consistent with that of silybin, and the cell survival rate is close to 100%. In addition, compound 2 and compound 3 have similar proliferation inhibition curves. Under the treatment of 120 μM concentration, they have cell survival rates of 80.1±1.2% and 82.6±1.7%, respectively, indicating that compounds 1 to 3 are almost non-toxic to HSC-T6 cells at concentrations of 20, 40, 80, and 120 μM.

[0117] Embodiment 18

[0118] Experimental study on acute liver injury induced by CCl4 in rats

[0119] 18.1 Experimental Methods

[0120] Twenty-four male SD rats were randomly divided into four groups, namely, blank control group, model group, silybin group and thiosilybin derivative group, with 6 rats in each group. After three days of animal adaptation, the rats in the blank control group and liver injury model group were intragastrically administered with 0.3% sodium carboxymethyl cellulose at a dose of 3ml / kg, and the rats in the experimental group were intragastrically administered with a drug suspension (3ml 0.3% sodium carboxymethyl cellulose suspension per 100mg of the drug) at a dose of 100mg / kg. Once a day for seven consecutive days. Two hours after the seventh day of administration, the blank control group rats were intraperitoneally injected with corn oil (2ml / kg), and the remaining rats were intraperitoneally injected with corn oil containing 50% CCl4 to induce acute liver injury. Then fasted but not watered, and weighed after 16h overnight. After 5% chloral hydrate anesthesia, 1 ml of blood was collected from the intercardiac space, placed in an EP tube moistened with EDTA and placed in an ice bath, centrifuged at 4°C, 8000 rpm / min for 10 min using a low-temperature centrifuge, and the upper serum was aspirated and frozen at -80°C.

[0121] Afterwards, the rats were killed with 10% chloral hydrate, dissected, and liver tissues were taken. After the livers were washed with physiological saline, the water was absorbed by filter paper, weighed, and photographed. After the rat livers were weighed, the left lobe of the rat liver was taken and immersed in 10% formalin tissue fixative for HE staining and Oil Red O staining sections. Another 100 mg of the right lobe of the rat liver was cut and placed in a grinding tube with physiological saline at a ratio of 1:9. After being evenly ground by a grinder, it was centrifuged at 3500r / min for 15 minutes, and the upper serum was aspirated and frozen at -80℃ for detection of SOD activity and MDA content. The oil drop area was counted, the data were processed and plotted, and all data were shown as the mean ± SD of six independent samples.

[0122] 18.2 Compound 2 reduces liver index in acute liver injury

[0123] The weight growth rate of SD rats during the experiment was as follows Figure 2 As shown in (A), during the administration period, the body weights of rats in the normal group, model group, silybin group, and compound 2 group increased steadily, and the growth rate was similar, indicating that compound 2 had no obvious toxic side effects when administered intragastrically at a dose of 100 mg / kg per day. Figure 2 (B) The results showed that compared with the normal group, the liver-to-body ratio of the model group rats increased significantly, indicating that the liver of the model group was damaged and swollen. Compared with the model group, the liver-to-body ratio of the rats treated with compound 2 was reduced, indicating that compound 2 can prevent liver enlargement caused by CCl4-induced acute liver injury and has a protective effect on the liver.

[0124] 18.3 Compound 2 improves liver tissue pathology in acute liver injury

[0125] Rat liver and pathological staining sections Figure 3(A) As shown. Compared with the normal group, the liver of the model group rats was pale and rough in appearance, while the liver of the rats after administration of compound 2 was smooth and ruddy, indicating that compound 2 can improve the appearance and morphology of the liver. The results of H&E staining showed that the liver tissue structure of the normal group rats was clear, the liver lobules were intact, the liver cell structure and morphology were normal, and there was no inflammation. The liver cells in the model group were obviously damaged, the liver tissue structure was disordered, the liver cells were swollen and necrotic, and there was inflammatory cell infiltration. The silybin group and the compound 2 group showed significant improvement, and fatty degeneration and inflammatory cell infiltration were significantly reduced, especially for compound 2, the improvement was more obvious. In addition, the statistical results of Oil Red O staining and oil droplet area are shown in Figure 2. Figure 3 (B) Compared with the normal group, the model group showed severe fat accumulation. Compound 2 could reduce fat deposition caused by acute liver injury and improve liver fatty degeneration, and its effect was better than silybin.

[0126] 18.4 Compound 2 improves serum biochemical parameters in acute liver injury

[0127] Indicators of liver damage such as Figure 4 Table 2. The results of plasma biochemical tests showed that compared with the normal group, the three liver injury indicators in the model group were significantly increased, indicating the occurrence of CCl4-induced acute injury, while the serum AST( Figure 4 (A))、ALT( Figure 4 (B)) and LDH( Figure 4 (C)) contents were significantly decreased, indicating that compound 2 has a good preventive effect on CCl4-induced acute injury and its effect is better than silybin.

[0128] Table 2 Effects of compound 2 on rat liver function indicators

[0129] Group ALT(U / L) AST(U / L) LDH(U / L) Normal group 134.6±29.6 57.4±10.3 210.0±81.0 Model Group 817.7±30.9 439.4±50.0 1153.1±197.8 Silybin group 658.7±60.6 196.5±70.7 392.9±128.5 Compound 2 524.7±133.2 144.6±62.2 300.5±140.1

[0130] 18.5 Compound 2 improves oxidative stress indicators in acute liver injury

[0131] The malondialdehyde (MDA) content and superoxide dismutase (SOD) activity in rat liver tissue homogenate were analyzed. Figure 5 As shown in Table 3, compared with the normal group, the MDA content in the liver of the model group was about 5 times that of the normal group, indicating that the lipid metabolism in the liver of the rats was abnormal, the degree of lipid peroxidation increased, and oxidative stress occurred; while the SOD activity decreased slightly, indicating that the antioxidant capacity in the rats was insufficient. Both compound 2 and silybin can reduce the MDA content in rats and restore the SOD activity, and compared with silybin, compound 2 has a more significant effect on improving oxidative stress in rats.

[0132] Table 3 Effects of A1 on oxidative stress indices in rats

[0133] Group MDA (nmol / mgprot) SOD (U / mgprot) Normal group 1.3±0.3 1733.9±218.5 Model Group 6.6±0.5 1327.8±95.3 Silybin group 4.4±0.4 1513.0±159.8 Compound 2 3.3±1.1 1793.7±122.8

[0134] Embodiment 19

[0135] Experimental study on chronic liver injury induced by CCl4 and high-fat diet in mice

[0136] 19.1 Experimental Methods

[0137] 32 C57BL / 6 mice (6w, 20-25g) were randomly divided into a normal group, a model group, a silybin group and a compound group 2, a total of 4 groups, 8 in each group. After the animals were adapted to the environment in a constant temperature breeding room for 3 days, they were fasted for 24h on the morning of the third day. On the morning of the fourth day, the normal group was given ordinary feed, and the other groups were given a high-fat diet. During this period, the mice were free to eat. The normal group was intraperitoneally injected with corn oil once a week at a dose of 0.01ml / g, and the other groups were intraperitoneally injected with 2% CCl4 once a week at the same dose to induce liver damage. The modeling lasted for 5 weeks, and the weight of the mice was recorded every day.

[0138] Five weeks after modeling, the normal group and model mice were gavaged with 0.3% (m) sodium carboxymethyl cellulose at a dose of 5 ml / kg, and the other groups of mice were gavaged with the corresponding drug suspension at a dose of 150 mg / kg (drug suspension: 150 mg of drug suspended in 5 ml 0.3% CMC-Na solution, ground evenly in a mortar), once a day for four weeks. The normal group continued to eat a normal diet, and the other groups continued to be given a high-fat diet plus intraperitoneal injection of CCl4 to maintain liver damage.

[0139] Four weeks after administration, after the last administration, the mice were fasted but not watered, and weighed after 16 hours overnight. After the mice died of carbon dioxide asphyxiation, about 1 ml of blood was immediately collected from the heart, and the blood was placed in an EP tube moistened with EDTA and placed in an ice bath. The blood was centrifuged at 8000 rpm / min for 10 minutes using a low-temperature centrifuge, and the upper serum was collected and frozen at -80°C.

[0140] Mice were dissected and liver tissue was taken. After the liver was washed with physiological saline, the water was absorbed by filter paper, weighed and photographed. The left lateral lobe of mouse liver was immersed in 10% formalin solution for making HE staining sections, Oil Red O staining sections and Masson staining sections. About 100 mg of the right lateral lobe of mouse liver was cut and placed in a centrifuge tube for freezing and used to detect SOD activity, MDA content and GSH-Px activity.

[0141] The oil droplet area and fibrosis area were counted, and the data were processed and plotted. All data were shown as the mean ± SD of eight independent samples.

[0142] 19.2 Compound 2 improves liver index in chronic liver injury

[0143] The weight growth rate of mice Figure 6(A) Compared with the normal group, the inhibitory effect of CCl4 on the weight gain rate of the model group mice is more and more significant. Compound 2 and silybin can reduce the toxicity of CCl4 to a certain extent. Figure 6 (B) The results showed that compared with the normal group, the liver-to-body ratio index of the model group increased significantly, while the liver-to-body ratio index of the treatment group was significantly improved compared with the model group, indicating that compound 2 can alleviate the enlargement of liver volume and fat deposition caused by long-term injection of CCl4, and the effect is comparable to that of silybin.

[0144] 19.3 Compound 2 improves the pathological morphology of liver tissue in chronic liver injury

[0145] The appearance of the liver of mice in each group was as follows Figure 7 (A), pathological staining sections Figure 7 (B) Compared with the normal group, the liver of the mice in the model group was pale and rough. H&E staining showed significant fatty degeneration, inflammatory cell infiltration and ballooning degeneration of hepatocytes, indicating severe damage and inflammation of the liver tissue. Oil red O staining showed a large amount of fat accumulation, indicating abnormal lipid metabolism in the mouse liver. Masson staining showed that a large amount of collagen fibers were produced in the mouse liver tissue, indicating the occurrence of liver fibrosis. Compared with the model group, the liver of mice treated with silybin and compound 2 was smoother and more rosy. The results of pathological sections showed that fatty degeneration was significantly improved in the compound 2 group, inflammatory cell infiltration was reduced, and fat deposition and collagen fibers were significantly reduced. The statistical results of fat droplet and collagen fiber area are shown in Figure 2. Figure 7 (C) and Figure 7 (D) The above results indicate that compound 2 can improve the pathological morphology of chronic liver injury induced by CCl4 plus high-fat diet in mice, and its effect is better than silybin.

[0146] 19.4 Compound 2 improves liver function indicators in chronic liver injury

[0147] like Figure 8 As shown in Table 4, compared with the normal group, the ALT ( Figure 8 (A))、AST( Figure 8 (B)) content was significantly increased, indicating the occurrence of liver damage. Silybin and compound 2 treatment could reduce the level of transaminase in plasma, and the effect of compound 2 was better than that of silybin.

[0148] Table 4 Effects of compound 2 on liver function indexes in mice

[0149]

[0150]

[0151] 19.5 Compound 2 improves blood lipid levels in chronic liver injury

[0152] like Fig. 9 As shown in Table 5, compared with the normal group, the levels of triglyceride (TG), cholesterol (CHO), and low-density lipoprotein (LDL) in the model group were increased, and the level of high-density lipoprotein (HDL) was decreased, indicating that the blood lipids of mice in this model increased significantly and there were problems with liver fat metabolism. Compound 2 improved the above indicators, and the effect was more obvious than that of silybin.

[0153] Table 5 Effects of compound 2 on blood lipid levels in mice

[0154] Group TG mmol / L CHO mmol / L LDL mmol / L HDL mmol / L Normal group 0.72±0.08 2.27±0.15 0.20±0.03 1.47±0.12 Model Group 1.33±0.10 3.15±0.23 0.47±0.06 0.93±0.22 Silybin group 1.01±0.13 2.54±0.10 0.39±0.03 1.21±0.12 Compound 2 0.86±0.08 2.39±0.14 0.30±0.02 1.43±0.12

[0155] 19.6 Compound 2 improves oxidative stress indicators in chronic liver injury

[0156] like Fig.10 As shown in Table 6, compared with the normal group, the liver MDA production of the model group mice was excessive, and the SOD activity and glutathione peroxidase (GSH-Px) activity decreased significantly, indicating abnormal liver lipid metabolism and severe oxidative stress. After treatment with silybin and compound 2, the MDA content was significantly reduced, and the SOD and GSH-Px activities returned to normal levels.

[0157] Table 6 Effects of compound 2 on oxidative stress indicators in mice

[0158] Group MDA (nmol / mgprot) SOD (U / mgprot) GSH-PX(U / mgprot) Normal group 0.38±0.05 758.02±79.11 237.52±23.76 Model Group 0.94±0.13 482.27±53.11 104.35±14.54 Silybin group 0.57±0.12 746.26±97.74 203.55±68.45 Compound 2 0.48±0.10 740.52±80.28 250.45±32.70

[0159] Embodiment 20

[0160] Pharmacokinetic properties of compound 2 in rats

[0161] 20.1 Solution preparation

[0162] (1) Preparation of Silybin and Compound 2 standard solutions: Weigh 10.0 mg of Silybin reference substance accurately, place it in a 10 mL volumetric flask, dilute it with methanol to a stock solution with a solubility of 1 mg / mL, dilute the stock solution with methanol in proportion, prepare Silybin standard solutions with concentrations of 200, 500, 1000, 2000, 4000, 10000, 20000, 100000 ng / mL, take 10 μL of each concentration standard solution, dilute it 20 times with blank plasma, and obtain plasma samples with blood drug concentrations of 10, 25, 50, 100, 200, 500, 1000, 5000 ng / mL. Prepare plasma samples with compound 2 concentrations of 50, 100, 250, 500, 1000, 2000, 5000, 10000 ng / mL in the same way. Store in a refrigerator at 4°C for use.

[0163] (2) Preparation of internal standard solution: Chlorzoxazone and carbamazepine were used as internal standards for silybin and compound 2, respectively. 25.0 mg of chlorzoxazone and carbamazepine reference substances were accurately weighed and placed in a 25 mL volumetric flask, dissolved with acetonitrile, and diluted to the mark to prepare an internal standard stock solution with a concentration of 1 mg / mL. 10 μL of the internal standard stock solution was placed in a 25 mL volumetric flask, diluted with acetonitrile, and diluted to the mark to prepare an internal standard solution with a concentration of 1000 ng / mL. The solution was then refrigerated in a 4°C refrigerator for later use.

[0164] 20.2 Plasma Sample Processing Methods

[0165] Take 100 μL of plasma sample and place it in a 1 mL centrifuge tube. Add 100 μL of acetonitrile and 100 μL of internal standard solution in sequence. Vortex and shake for 1 min. Then, rotate at 13000 r·min- 1 After centrifugation for 5 min, 150 μL of the supernatant was taken for analysis.

[0166] 20.3 Chromatographic conditions

[0167] (1) Chromatographic column: YMC-Pack ODS-AQ 250*4.6mm LDS-5μm, 12nm

[0168] (2) The mobile phase was acetonitrile (A): 0.1% trifluoroacetic acid in water (B); the flow rate was 1 mL min- 1 ; Injection volume: 10 μL; Column temperature: 25°C. Silybin isocratic elution: 30% (v / v) A; The gradient elution program of compound 2 is shown in Table 7.

[0169] Table 7 Gradient elution program of compound 2

[0170] Time (min) <![CDATA[Flow rate (mL·min- 1 )]]> A(%) B(%) 0.00 1.00 40.0 60.0 5.00 1.00 50.0 50.0 12.00 1.00 60.0 40.0 14.00 1.00 40.0 60.0

[0171] 20.4 Experimental Methods

[0172] Twelve male SD rats were randomly divided into two groups, namely, silibinin group and compound 2 group, with 6 rats in each group. After the animals were adapted to the environment for three days, they were intragastrically administered at a dose of 150 mg / kg. About 300 μL of blood was collected from the retro-orbital venous plexus of the silibinin group at 0.33h, 1h, 2h, 3h, 4h, 6h, 8h, and 12h after administration, and blood was collected from the compound 2 group at 0.1h, 0.33h, 1h, 2h, 3h, 4h, 5h, 6h, 8h, and 12h after administration. The blood was placed in an EP tube moistened with EDTA and placed in an ice bath. The blood was centrifuged at 8000rpm·min- 1 Centrifuge for 10 minutes, draw up the upper serum and freeze at -20℃. Process it according to the method described in 19.2 for analysis. Fit the mean blood drug concentration data with a non-compartmental model and calculate the pharmacokinetic parameters of each component.

[0173] 20.5 Experimental Results

[0174] The blood concentration-time curves of silybin and compound 2 are shown in Fig.11 The pharmacokinetic parameters are shown in Table 8. The results of the in vivo pharmacokinetic experiment in rats showed that the Cmax, AUC 0-8 h were 21 and 28 times that of silybin, respectively, indicating that the absorption of compound 2 in rats was significantly improved compared with silybin. Using the formula (relative bioavailability = AUC 0-8 h derivative / AUC 0-8 The relative bioavailability was calculated by silybin (h prototype drug * 100%), and the relative bioavailability of compound 2 was 2813%. The results showed that compared with silybin, the oral bioavailability of compound 2 was significantly improved.

[0175] Table 8 Pharmacokinetic parameters of silybin and compound 2 in rats

[0176] Pharmacokinetic parameters Silybin Compound 2 <![CDATA[AUC 0-8 h,ng / mL*h]]> 390.55±72.61 10971.66±1593.28 <![CDATA[AUC 0-∞ ,ng / mL*h]]> 494.23±129.46 11599.60±1758.88 <![CDATA[MRT 0-∞ ,h]]> 5.22±2.20 3.51±0.25 <![CDATA[t 1 / 2 ,h]]> 2.45±0.03 1.55±0.13 Cmax,ng / mL 194.34±23.06 4081.01±855.28 Vz / F,L 446.72±241.20 6.91±1.37 CLz / F,L / h 74.79±19.35 3.08±0.49

Claims

1. A new class of sulfur-containing silybin derivatives, It is characterized in that The structure of the novel sulfur-containing silybin derivative is shown in formula (I): Among them, (1) C 2 -C 3 There is a carbon-carbon single bond -CH-CH- or a carbon-carbon double bond -C=C- between them; (2)R 1 is H, fatty acyl, aromatic acyl, sulfonyl, carbamoyl, thiocarbamoyl or R 4 , R 4 As shown below: (3)R 2 , R 3 It is H or alkyl substituted amine methylene.

2. The novel sulfur-containing silybin derivative according to claim 1, It is characterized in that The novel sulfur-containing silybin derivatives include compounds shown in 1 to 15:

3. The method for preparing the novel sulfur-containing silybin derivative according to claim 1, It is characterized in that The method comprises the following steps: (1) Preparation of Compounds 1 and 4 Under the protection of nitrogen, triphenylphosphine is dissolved in anhydrous tetrahydrofuran, and diisopropyl azodicarboxylate is slowly added dropwise under the condition of stirring in an ice bath. After the addition is completed, a white precipitate is observed to be generated; then, silybin or 2,3-dehydrosilybin dissolved in anhydrous tetrahydrofuran is added to the reaction solution, and finally thioacetic acid is added, and the reaction is restored to room temperature and continued for 30 minutes; after the reaction is completed, it is extracted with ethyl acetate, the organic phases are combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent is spin-dried and separated and purified by silica gel column chromatography to obtain compound 1 or 4; the molar mass ratio of silybin or 2,3-dehydrosilybin, triphenylphosphine, diisopropyl azodicarboxylate, and thioacetic acid is 1:1-6:1-6:1-6, and the amount of the solvent tetrahydrofuran is 1-50 ml of tetrahydrofuran per 1 gram of silybin; (2) Preparation of Compounds 2 and 5 Dissolve compound 1 or compound 4 in 1M HCl / MeOH solution and stir at room temperature for 3-4h; extract with ethyl acetate after the reaction is completed, combine the organic phases, wash with saturated brine, dry with anhydrous sodium sulfate, spin dry the solvent, and separate and purify by silica gel column chromatography to obtain compound 2 or 5. The amount of 1M HCl / MeOH solution used is 1-50 ml per 1 gram of compound 1 or 4; (3) Preparation of Compounds 3 and 6 Compound 2 or compound 5 is subjected to a condensation reaction under the action of an oxidizing agent, iodine, for about 10 to 20 minutes. After the reaction is completed, the mixture is quenched with a saturated sodium thiosulfate solution, extracted with ethyl acetate, the organic phases are combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent is spin-dried to obtain compound 3 or 6; the molar mass ratio of the compound 2 or 5 to the iodine element is 1:0.1 to 3, and the solvent used is dimethyl sulfoxide, and 1 to 50 ml of the solvent dimethyl sulfoxide is used for every 500 mg of compound 2 or 5; (4) Preparation of compounds 7 to 15 Compound 1 or compound 2 is dissolved in methanol, and 37% formaldehyde aqueous solution and corresponding secondary amine are added in sequence, and the reaction is carried out at room temperature for 12 to 30 hours. After the reaction is completed, it is extracted with dichloromethane, the organic phases are combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent is spin-dried and separated and purified by silica gel column chromatography to obtain compounds 7 to 15; the molar mass ratio of the compound 1 or 2, 37% formaldehyde aqueous solution, and the corresponding secondary amine is 1:0.5-4:0.5-4, and the amount of methanol solvent used is 1-25 ml for every 250 mg of compound 1 or 2.

4. Use of the novel sulfur-containing silybin derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1 or 2 in the preparation of a liver protection drug for preventing and treating acute and chronic liver damage caused by various reasons, including non-alcoholic steatohepatitis, alcoholic steatohepatitis, drug-induced liver damage, liver fibrosis and cirrhosis.

Citation Information

Patent Citations

  • Silibinin 3,3′-thiodipropionic acid ester with hepatoprotective activity and a method of preparing the same

    US10766885B1